Skip to main content
Drug Design, Development and Therapy logoLink to Drug Design, Development and Therapy
. 2015 Apr 2;9:1865. doi: 10.2147/DDDT.S84395

Profile of atacicept and its potential in the treatment of systemic lupus erythematosus [Corrigendum]

PMCID: PMC4396419  PMID: 25897201

Cogollo E, Silva MA, Isenberg D. Drug Design, Develop ment and Therapy. 2015;9:1331–1339.

The author list contained a spelling error: Estafania Cogollo should be Estefania Cogollo.

On page 1337, first column: “Only two patients reached IgG levels below 3 g/L and, even in those, no serious infections were reported. Of note, the infections in the two patients who died were not associated with hypergammaglobulinemia” – “hypergammaglobulinemia” should be “hypogammaglobulinemia”.

On page 1337, second column: “Furthermore, hypergammaglobulinemia has been reported in approximately half of renal transplant patients who received MMF and steroids and an increased risk of infection has been observed in other LN studies during the induction phase with MMF and high-dose CS” – “hypergammaglobulinemia” should be “hypogammaglobulinemia”.


Articles from Drug Design, Development and Therapy are provided here courtesy of Dove Press

RESOURCES